We are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have […]

We are a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. We developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.  We believe the novel coronavirus, or COVID-19, pandemic has […]

We are an advertising software company. Our software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Programmatic advertising is rapidly taking market share from traditional ad sales channels, which require more staffing, offer less transparency and involve higher costs to buyers. Our demand side platform (“DSP”), Adelphic, is […]

We are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. NASH is a severe form of non-alcoholic fatty liver disease, or NAFLD, that affects up to 15 million people in the United States, and up to 6% of the global population, for […]

We are a late-stage biotechnology company pioneering the development of a novel class of TCR (T cell receptor) bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including […]

Note: This is the third blank-check company put together by Barry S. Sternlicht, the founder and former chairman and CEO of Starwood Hotels & Resorts Worldwide. (This blank-check company is incorporated in the Cayman Islands.) From the prospectus: Our sponsor, Mustang Sponsor LLC, is an affiliate of Jaws Estates Capital, the family office of Barry S. […]

We are a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. We […]

We are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the immune system’s strength by activating and recruiting myeloid cells to […]

Vor Biopharma’s mission is to develop transformative treatments for patients suffering from hematological malignancies. We are a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure […]

We are a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. We aim to inhibit the inflammatory responses by changing the metabolic processes in target cells. Through our […]